Analysts Set MBX Biosciences, Inc. (NYSE:MBX) PT at $37.63

Shares of MBX Biosciences, Inc. (NYSE:MBX) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $37.75.

Several analysts have recently commented on the stock. Jefferies Financial Group assumed coverage on shares of MBX Biosciences in a research note on Friday. They issued a “buy” rating and a $36.00 target price for the company. Oppenheimer assumed coverage on shares of MBX Biosciences in a research note on Wednesday, July 16th. They issued an “outperform” rating and a $38.00 target price for the company. Finally, Mizuho assumed coverage on shares of MBX Biosciences in a research note on Tuesday, August 5th. They issued an “outperform” rating and a $38.00 target price for the company.

Hedge Funds Weigh In On MBX Biosciences

Large investors have recently made changes to their positions in the stock. Nuveen Asset Management LLC purchased a new position in shares of MBX Biosciences in the 4th quarter valued at about $267,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in MBX Biosciences during the 4th quarter valued at about $117,000. Citadel Advisors LLC increased its holdings in MBX Biosciences by 62.5% during the 4th quarter. Citadel Advisors LLC now owns 220,330 shares of the company’s stock valued at $4,061,000 after acquiring an additional 84,722 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in MBX Biosciences during the 4th quarter valued at about $27,000. Finally, Deutsche Bank AG purchased a new position in MBX Biosciences during the 4th quarter valued at about $80,000.

MBX Biosciences Price Performance

Shares of NYSE:MBX opened at $14.72 on Wednesday. MBX Biosciences has a 1-year low of $4.81 and a 1-year high of $27.50. The stock has a market cap of $494.50 million and a P/E ratio of -3.24. The firm has a fifty day moving average price of $12.21 and a 200 day moving average price of $10.62.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.